

**Complete Accounts of Integrated Drug Discovery
and Development: Recent Examples from the
Pharmaceutical Industry
Volume 3**



Library of Congress Cataloging-in-Publication Data

Names: Pesti, Jaan A., 1954- editor. | Abdel-Magid, Ahmed F., 1947- editor. | Vaidyanathan, Rajappa, editor. | American Chemical Society, issuing body. | American Chemical Society. Division of Organic Chemistry, sponsoring body.

Title: Complete accounts of integrated drug discovery and development : recent examples from the pharmaceutical industry, vol. 3/
Jaan A. Pesti, editor, Pharma Resource Group, Inc., Drexel Hill, Pennsylvania, United States, Ahmed F. Abdel-Magid, editor, Therachem Research Medilab, LLC, Chelsea, Alabama, United States, Rajappa Vaidyanathan, editor, Medicines for All Institute, Virginia Commonwealth University, Richmond, Virginia, United States ; sponsored by the ACS Division of Organic Chemistry.

Description: Washington, DC : American Chemical Society, [2018-] | Series: ACS symposium series ; 1369 | Includes bibliographical references and index.

Identifiers: LCCN 2018048857 (print) | LCCN 2018050283 (ebook) | ISBN 9780841298637 (ebook) | ISBN 9780841298644 (hardcover OP) | ISBN 9781713888918 (pod)

Subjects: LCSH: Drug development. | Pharmaceutical industry. | Pharmaceutical technology.

Classification: LCC RM301.25 (ebook) | LCC RM301.25 .C66 2018 (print) | DDC 615.1/9--dc23

LC record available at <https://lccn.loc.gov/2018048857>

The paper used in this publication meets the minimum requirements of American National Standard for Information Sciences—Permanence of Paper for Printed Library Materials, ANSI Z39.48n1984.

Copyright © 2020 American Chemical Society

All Rights Reserved. Reprographic copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Act is allowed for internal use only, provided that a per-chapter fee of \$40.25 plus \$0.75 per page is paid to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA. Republication or reproduction for sale of pages in this book is permitted only under license from ACS. Direct these and other permission requests to ACS Copyright Office, Publications Division, 1155 16th Street, N.W., Washington, DC 20036.

The citation of trade names and/or names of manufacturers in this publication is not to be construed as an endorsement or as approval by ACS of the commercial products or services referenced herein; nor should the mere reference herein to any drawing, specification, chemical process, or other data be regarded as a license or as a conveyance of any right or permission to the holder, reader, or any other person or corporation, to manufacture, reproduce, use, or sell any patented invention or copyrighted work that may in any way be related thereto. Registered names, trademarks, etc., used in this publication, even without specific indication thereof, are not to be considered unprotected by law.

PRINTED IN THE UNITED STATES OF AMERICA

Contents

Preface	ix
1. Discovery and Chemical Development of the Use-Dependent Sodium Channel Blocker Vixotrigine for the Treatment of Pain	1
David R. Witty, David T. MacPherson, Gerard M. P. Giblin, Michael T. Williams, Robbie Chen, Vinny Couming, John Guzowski, Erwin Irdam, William F. Kiesman, Daw-Iong Albert Kwok, Wenli Liang, Tamera L. Mack, Erin M. O'Brien, Suzanne M. Opalka, Daniel Patience, Stefan Sahli, Donald G. Walker, and Frederick Osei-Yeboah	
2. The Discovery and Chemical Development of BMS-919373: A Selective I_{Kur} Inhibitor for the Potential Treatment of Atrial Fibrillation	43
Heather J. Finlay, Scott A. Savage, Jason M. Stevens, Steven R. Wisniewski, and Miao Yu	
3. Discovery and Development of Omecamtiv Mecarbil: A Novel Cardiac Myosin Activator for the Potential Treatment of Systolic Heart Failure	99
Bradley P. Morgan, Seb Caille, and Shawn D. Walker	
4. Identification and Development of AMG 986: A Potent and Efficacious APJ Agonist for the Treatment of Heart Failure	127
Matthew R. Kaller, Paul Dransfield, Robert P. Farrell, and Ted C. Judd	
5. Melflufen: A Journey from Discovery to Multi-Kilogram Production.....	157
Fredrik Lehmann and Johan Wennerberg	
6. Discovery and Chemical Development of S 44563, a Dual Bcl-2/Bcl-xL Inhibitor	179
Christophe Hardouin and Jérôme-Benoît Starck	
7. Discovery and Chemical Development of Tesirine: An Antitumor Pyrrolobenzodiazepine Antibody-Drug Conjugate Drug-Linker.....	215
Arnaud C. Tiberghien and Jeremy S. Parker	
8. Discovery and Chemical Development of Relebactam: A Potent β-Lactamase Inhibitor in Combination with Primaxin[®] for the Treatment of Serious and Antibiotic-Resistant Bacterial Infections	253
Feng Xu, Benjamin D. Sherry, and Timothy A. Blizzard	
9. Discovery and Chemical Development of Grazoprevir: An HCV NS3/4a Protease Inhibitor for the Treatment of the Hepatitis C Virus Infection	285
Feng Xu and John A. McCauley	

10. Discovery and Process Development of BIIB068: A Reversible Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Autoimmune Diseases	313
Bin Ma, Chaomin Li, Brian T. Hopkins, Lloyd Franklin, Robbie Chen, Tamera Mack, Daniel Patience, William F. Kiesman, and Erin M. O’Brien	
11. Discovery and Commercial Development of Cholesteryl Transfer Protein Inhibitor Evacetrapib	339
Nathan B. Mantlo and Scott A. Frank	
Editors’ Biographies	373

Indexes

Author Index.....	377
Subject Index	379